{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:14:24Z","timestamp":1762506864695,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ejogrb.2016.08.013","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T22:14:51Z","timestamp":1470780891000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluation of the effects of cabergoline (Dostinex) on women with symptomatic myomatous uterus: a randomized trial"],"prefix":"10.1016","volume":"206","author":[{"given":"Mansureh","family":"Vahdat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Kashanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negar","family":"Ghaziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narges","family":"Sheikhansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejogrb.2016.08.013_bib0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1080\/00016340802146912","article-title":"Modern management of uterine fibroids","volume":"87","author":"Levy","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"January (6)","key":"10.1016\/j.ejogrb.2016.08.013_bib0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/IJWH.S51083","article-title":"Uterine fibroids: current perspectives","volume":"29","author":"Khan","year":"2014","journal-title":"Int J Womens Health"},{"issue":"June (8)","key":"10.1016\/j.ejogrb.2016.08.013_bib0015","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1289\/ehp.5787","article-title":"Etiology and pathogenesis of uterine leiomyomas: a review","volume":"111","author":"Flake","year":"2003","journal-title":"Environ Health Perspect"},{"issue":"December (6)","key":"10.1016\/j.ejogrb.2016.08.013_bib0020","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0015-0282(03)02207-6","article-title":"Uterine fibroids and gynecologic pain symptoms in a population-based study","volume":"80","author":"Lippman","year":"2003","journal-title":"Fertil Steril"},{"issue":"October (10)","key":"10.1016\/j.ejogrb.2016.08.013_bib0025","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/humrep\/deh407","article-title":"Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study","volume":"19","author":"Marino","year":"2004","journal-title":"Hum Reprod"},{"issue":"September (1)","key":"10.1016\/j.ejogrb.2016.08.013_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","article-title":"EMAS position statement: management of uterine fibroids","volume":"79","author":"P\u00e9rez-L\u00f3pez","year":"2014","journal-title":"Maturitas"},{"issue":"February (2)","key":"10.1016\/j.ejogrb.2016.08.013_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"issue":"December (2)","key":"10.1016\/j.ejogrb.2016.08.013_bib0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejogrb.2012.07.030","article-title":"Therapeutic management of uterine fibroid tumors: updated French guidelines","volume":"165","author":"Marret","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"October","key":"10.1016\/j.ejogrb.2016.08.013_bib0045","first-page":"CD005287","article-title":"Selective estrogen receptor modulators (SERMs) for uterine leiomyomas","volume":"10","author":"Deng","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"August","key":"10.1016\/j.ejogrb.2016.08.013_bib0050","first-page":"CD007687","article-title":"Mifepristone for uterine fibroids","volume":"8","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"April","key":"10.1016\/j.ejogrb.2016.08.013_bib0055","first-page":"CD005292","article-title":"Herbal preparations for uterine fibroids","volume":"4","author":"Liu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"February","key":"10.1016\/j.ejogrb.2016.08.013_bib0060","first-page":"CD008994","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","volume":"2","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"April","key":"10.1016\/j.ejogrb.2016.08.013_bib0065","first-page":"CD002126","article-title":"Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding","volume":"4","author":"Lethaby","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"January (1)","key":"10.1016\/j.ejogrb.2016.08.013_bib0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.fertnstert.2008.09.064","article-title":"A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status","volume":"93","author":"Parsanezhad","year":"2010","journal-title":"Fertil Steril"},{"issue":"October","key":"10.1016\/j.ejogrb.2016.08.013_bib0075","first-page":"CD009505","article-title":"Aromatase inhibitors for uterine fibroids","volume":"10","author":"Song","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"January (1)","key":"10.1016\/j.ejogrb.2016.08.013_bib0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2007.11.006","article-title":"Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients","volume":"91","author":"Hil\u00e1rio","year":"2009","journal-title":"Fertil Steril"},{"issue":"October (4)","key":"10.1016\/j.ejogrb.2016.08.013_bib0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1472-6483(10)60246-5","article-title":"Treatment of symptomatic uterine leiomyoma with letrozole","volume":"17","author":"Gurates","year":"2008","journal-title":"Reprod Biomed Online"},{"issue":"December (2)","key":"10.1016\/j.ejogrb.2016.08.013_bib0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejogrb.2013.09.010","article-title":"Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women","volume":"171","author":"Duhan","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"July (1)","key":"10.1016\/j.ejogrb.2016.08.013_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/uog.10145","article-title":"Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study","volume":"40","author":"Brito","year":"2012","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"February (1)","key":"10.1016\/j.ejogrb.2016.08.013_bib0100","first-page":"51","article-title":"Aromatase and leiomyoma of the uterus","volume":"22","author":"Shozu","year":"2004","journal-title":"Semin Reprod Med"},{"issue":"September (3)","key":"10.1016\/j.ejogrb.2016.08.013_bib0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.AOG.0000279151.20878.60","article-title":"The effect of anastrazole on symptomatic uterine leiomyomata","volume":"110","author":"Varelas","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"September\u2013October (5)","key":"10.1016\/j.ejogrb.2016.08.013_bib0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jmig.2009.05.009","article-title":"Aromatase inhibitors: potential reproductive implications","volume":"16","author":"Bedaiwy","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"issue":"December (51\u201352)","key":"10.1016\/j.ejogrb.2016.08.013_bib0115","first-page":"877","article-title":"The conservative and interventional treatment of fibroids","volume":"111","author":"Boosz","year":"2014","journal-title":"Dtsch Arzteblatt Int"},{"issue":"September (Suppl. 3)","key":"10.1016\/j.ejogrb.2016.08.013_bib0120","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.4103\/2141-9248.141955","article-title":"Pharmacological treatment of uterine fibroids","volume":"4","author":"Moroni","year":"2014","journal-title":"Ann Med Health Sci Res"},{"issue":"July (3)","key":"10.1016\/j.ejogrb.2016.08.013_bib0125","first-page":"CD007692","article-title":"Danazol for uterine fibroids","author":"Ke","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"August (8)","key":"10.1016\/j.ejogrb.2016.08.013_bib0130","first-page":"1024","article-title":"Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes","volume":"30","author":"Sayyah-Melli","year":"2009","journal-title":"Saudi Med J"},{"issue":"November (11)","key":"10.1016\/j.ejogrb.2016.08.013_bib0135","first-page":"1593","article-title":"Prolactin receptors in uterine leiomyomas","volume":"29","author":"Baban","year":"2008","journal-title":"Saudi Med J"},{"issue":"2","key":"10.1016\/j.ejogrb.2016.08.013_bib0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000010154","article-title":"Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells","volume":"48","author":"Nowak","year":"1999","journal-title":"Gynecol Obstet Investig"},{"key":"10.1016\/j.ejogrb.2016.08.013_bib0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2012\/943635","article-title":"Innovative oral treatments of uterine leiomyoma","volume":"2012","author":"Sabry","year":"2012","journal-title":"Obstet Gynecol Int"},{"issue":"4","key":"10.1016\/j.ejogrb.2016.08.013_bib0150","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bpobgyn.2008.03.001","article-title":"Medical management of fibroids","volume":"22","author":"Sankaran","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"March (3)","key":"10.1016\/j.ejogrb.2016.08.013_bib0155","first-page":"445","article-title":"Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression","volume":"28","author":"Melli","year":"2007","journal-title":"Saudi Med J"},{"issue":"September (Suppl. 3)","key":"10.1016\/j.ejogrb.2016.08.013_bib0160","first-page":"S33","article-title":"Effectiveness of dopamine agonist, Cabergoline (Dostinex) treatment on uterine myoma regression in comparison to the effect of gonadotrophin-releasing hormone analog (GnRHa) goserelin (Zoladex)","volume":"100","author":"Elbareg","year":"2013","journal-title":"Fertil Steril"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516308612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516308612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:37:46Z","timestamp":1759556266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211516308612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"alternative-id":["S0301211516308612"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.08.013","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the effects of cabergoline (Dostinex) on women with symptomatic myomatous uterus: a randomized trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}